Related Experiment Videos
Identifying and managing patients with hyperlipidemia
1Department of Pharmacy Services, Veteran's Affairs Medical Center, Memphis, TN, USA.
Insights
Lowering high lipid levels is crucial for preventing cardiovascular disease. Lifestyle changes and medication, guided by National Cholesterol Education Panel (NCEP) guidelines, effectively manage hyperlipidemia and reduce heart risks.
Area of Science:
- Cardiology
- Metabolic Disorders
- Public Health
Background:
- Hyperlipidemia significantly contributes to cardiovascular disease morbidity and mortality in the U.S.
- Clinical trials confirm the benefits of lipid level reduction in diverse patient populations.
- The National Cholesterol Education Panel (NCEP) was established to create guidelines for lipid disorder management.
Purpose of the Study:
- To outline the identification and treatment strategies for hyperlipidemia.
- To emphasize the importance of lifestyle modifications and pharmacologic interventions.
- To present the NCEP guidelines for managing lipid disorders.
Main Methods:
- Evaluation for secondary causes of hyperlipidemia before treatment.
- Identification of cardiovascular disease risk factors to set low-density lipoprotein (LDL) goals.
- Implementation of NCEP's two-step dietary plan to reduce cholesterol and fat intake.
- Incorporation of nonpharmacologic treatments: exercise, weight reduction, alcohol moderation, smoking cessation.
- Consideration of pharmacologic therapy for patients unresponsive to lifestyle changes.
- Review of principal lipid-lowering agents: bile acid sequestrants, nicotinic acid, HMG CoA reductase inhibitors, fibric acid derivatives.
Main Results:
- Dietary changes are the cornerstone of hyperlipidemia treatment.
- Pharmacoeconomic studies demonstrate that lipid-lowering therapy reduces medical interventions.
- Estrogen, fish oil, and alcohol may also reduce heart disease risk.
Conclusions:
- Comprehensive management of hyperlipidemia involves lifestyle changes and, when necessary, pharmacologic therapy.
- Adherence to NCEP guidelines is essential for effective lipid disorder management.
- Effective hyperlipidemia treatment can decrease healthcare utilization and costs associated with cardiovascular disease.
Abstract:
Cardiovascular disease related to hyperlipidemia is a significant cause of morbidity and mortality in the United States. The benefit of lowering lipid levels in patients with and without cardiovascular disease has been demonstrated in numerous clinical trials. The results of these trials prompted the National Heart, Blood, and Lung Institute to form the Nation Cholesterol Education Panel (NCEP). This panel developed guidelines for identifying and treating lipid disorders. Before starting antilipemic therapy, patients should be evaluated for secondary causes of hyperlipidemia, including disease states and medications. Risk factors for cardiovascular disease should be identified and used to determine the patient's goal low-density lipoprotein level. Regardless of the drug therapy used, the cornerstone treatment for hyperlipidemia is dietary changes. The NCEP recommendation for dietary modification follows a two-step plan to reduce intake of cholesterol and dietary fats. Other nonpharmacologic treatments for hyperlipidemia include exercise, weight reduction for obese patients, reduction of excessive alcohol use, and smoking cessation . Drug therapy should be considered in patients who do not respond to an adequate trial of dietary modifications and lifestyle changes. The principal lipid-lowering agents currently used are the bile acid sequestrants, nicotinic acid, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, and fibric acid derivatives. Estrogen, fish oil, and alcohol also can decrease the risk of developing heart disease. In pharmacoeconomic studies, lipid-lowering drug therapy has been shown to decrease the number of procedures, hospitalizations, and other medical interventions required by patients with cardiovascular disease.